Back to search
FDAFDA · Food and drugs·Recall number D-0265-2023

Atropine Sulfate Ophthalmic Solution, USP 1%, For Topical Application To The Eye, 2 mL bottle, Sterile, Rx only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. NDC: 17478-215-02

Published February 15, 2023 · Recall initiated: January 30, 2023

Summary

FDA records drug Class III recall D-0265-2023, published February 15, 2023 and initiated January 30, 2023. Recalling firm: Akorn, Inc.; Status: Ongoing; Reported quantity: 45,117 Bottles; Lot: Lot: 081031A, Exp 2/28/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Akorn, Inc.
Distributor
Nationwide in the USA and Puerto Rico
Lot
Lot: 081031A, Exp 2/28/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Atropine Sulfate Ophthalmic Solution, USP 1%, For Topical Application To The Eye, 2 mL bottle, Sterile, Rx only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. NDC: 17478-215-02 recalled?

Yes. FDA published recall D-0265-2023 on February 15, 2023. Reported hazard: Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint.

What should I do if I have this product?

Voluntary: Firm initiated · Letter